Companion Diagnostics Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — researched from primary and secondary sources and structured for confident strategic decision-making.
Market Snapshot
2025 Market Size
US$ 8.1 billion
Estimated Base Value
2035 Forecast
US$ 45.5 billion
Projected Market Value
CAGR 2026–2035
18.8%
Compound Annual Growth
Largest Segment
Polymerase Chain Reaction-based Diagnostics
Fastest Growing Segment
In Situ Hybridization-Based Diagnostics
Leading Region
North America
Fastest Growing Region
Emerging Areas
Top Country
United States
By Market Share
36.5% market share
Key Players
Qiagen
Emerging Players
Personalis, Burning Rock Biotech
Market Definition & Overview
The Companion Diagnostics (CDx) Market focuses on in vitro diagnostic devices used to identify patients most likely to benefit from a particular therapeutic product, or conversely, those at increased risk of serious adverse reactions. These diagnostics are co-developed and approved alongside specific drugs, primarily for personalized medicine. The market encompasses the research, development, manufacturing, and commercialization of these tests, enabling clinicians to tailor treatments based on individual patient biomarkers. Key applications span oncology, immunology, infectious diseases, and neurology, driving precision medicine by optimizing drug efficacy and enhancing patient safety.
Scope
- Global market coverage across all major regions
- Analysis segmented by technology, disease indication, and end-user
- Market sizing and forecast period spanning 2023-2033
Inclusions
- FDA-approved and CE-marked companion diagnostic kits
- Reagents and consumables specifically designed for CDx testing
- CDx development, validation, and regulatory approval services
- Bioinformatics and software platforms for CDx data interpretation
- Clinical laboratory testing services for companion diagnostics
- Molecular diagnostics co-developed with specific therapeutic drugs
Exclusions
- General in vitro diagnostics not linked to a specific drug
- Stand-alone biomarker tests without an associated therapeutic
- Non-diagnostic medical devices (e.g., surgical tools, implants)
- Pharmaceutical drug development not involving CDx co-development
- Research-use-only (RUO) diagnostic assays without clinical approval
Market Size Forecast
Executive Summary
• The Companion Diagnostics market is valued at $8.1 Bn in 2025 and is forecast to reach $45.5 Bn by 2035, reflecting a robust CAGR of 18.8% as demand accelerates across every major segment and region over the ten-year outlook.
• Polymerase Chain Reaction-based Diagnostics leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• North America commands the largest regional share at 38.5%, while Emerging Areas is expanding the fastest at a 10.5% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at 36.5% of global share, anchoring overall demand within its home region throughout the forecast period.
• The CDx market increasingly sees strategic partnerships between pharma and diagnostics firms, driving co-development and accelerating market entry for novel targeted therapies, shaping a highly collaborative yet competitive landscape across key therapeutic areas.
• Next-generation sequencing and multi-omic profiling platforms are pivotal growth catalysts, expanding CDx utility beyond oncology into broader therapeutic applications, fostering precision medicine across diverse patient populations globally.
• Evolving regulatory harmonization and reimbursement frameworks, particularly in advanced economies and emerging APAC markets, are critical for accelerating CDx adoption and ensuring equitable access to personalized treatment options worldwide.
• While oncology remains the dominant segment, significant R&D investment is shifting towards developing CDx for autoimmune, infectious, and neurological diseases, diversifying future market opportunities and patient benefits.
• Robust investment in AI-driven biomarker discovery and localized manufacturing capabilities is crucial for enhancing CDx development efficiency and fortifying resilient global supply chains against unforeseen disruptions.
• Integrating CDx into routine clinical practice requires overcoming persistent challenges related to data interoperability, physician education, and payer acceptance, demanding a multi-stakeholder strategic imperative for widespread adoption.
Key Market Takeaways
Critical findings and data points from this market research study.
Base Year Valuation
The Companion Diagnostics Market was valued at $8.1 billion in the base year, establishing a significant foundation for future expansion.
Future Market Reach
The market is projected to achieve a substantial valuation of $45.5 billion by the forecast year, indicating vast growth potential.
Rapid Growth Trajectory
Exhibiting a robust Compound Annual Growth Rate (CAGR) of 18.8%, the Companion Diagnostics Market is set for accelerated expansion.
Market Growth Outlook
The Companion Diagnostics Market is poised for significant growth, rising from $8.1 billion in the base year to $45.5 billion by the forecast year at an impressive 18.8% CAGR.
Oncology Dominance
The oncology segment is expected to continue its prominence within the Companion Diagnostics Market, driven by the increasing demand for personalized cancer therapies.
Personalized Medicine Driver
The increasing integration of personalized medicine approaches and the discovery of novel biomarkers are key trends propelling the Companion Diagnostics Market forward.
Market Dynamics
Market Trends
- Increased adoption of precision medicine for targeted therapies.
- Integration of AI and big data in diagnostic development.
- Growing shift towards non-invasive liquid biopsy tests.
- Rising demand for companion diagnostics in immunotherapy.
Growth Drivers
- Increasing prevalence of cancer and chronic diseases.
- Growing demand for personalized and targeted therapies.
- Favorable regulatory landscape and expedited approvals.
- Rapid technological advancements in diagnostic platforms.
Restraints
- High development costs and lengthy regulatory processes hinder market expansion.
- Complex reimbursement policies and coverage uncertainties limit broader adoption.
- Lack of standardization across different tests creates implementation challenges.
- Limited physician awareness and education impede widespread CDx utilization.
Opportunities
- Development of novel multi-omics companion diagnostic solutions.
- Expansion into untapped emerging markets and regions.
- Strategic collaborations between pharmaceutical and diagnostic firms.
- Application of CDx in infectious diseases and rare disorders.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Polymerase Chain Reaction-Based DiagnosticsImmunohistochemistry-Based DiagnosticsIn Situ Hybridization-Based DiagnosticsNext-Generation Sequencing-Based DiagnosticsFluorescence in Situ Hybridization-Based DiagnosticsMicroarray-Based DiagnosticsMass Spectrometry-Based DiagnosticsOther Molecular Diagnostics |
| By Application | OncologyNeurologyInfectious DiseasesCardiovascular DiseasesInflammatory & Autoimmune DiseasesGenetic DisordersReproductive HealthOther Therapeutic Areas |
| By End-User | Pharmaceutical & Biopharmaceutical CompaniesContract Research OrganizationsDiagnostic LaboratoriesHospitals & ClinicsAcademic & Research InstitutesCancer Research CentersGovernment & Regulatory BodiesOthers |
| By Component | Assay KitsReagentsInstrumentsSoftwareServicesControls & StandardsData Analysis & Interpretation ToolsOthers |
| By Disease Area | Lung CancerBreast CancerColorectal CancerMelanomaProstate CancerGastric CancerOvarian CancerOther Cancers & Non-Oncology Indications |
| By Sample Type | Tissue BiopsyLiquid BiopsyFormalin-Fixed Paraffin-Embedded TissueFresh Frozen TissueBone MarrowSalivaOther Biological Fluids |
Regional Analysis
- North America leads the companion diagnostics market, propelled by its well-established healthcare infrastructure, high R&D spending, and early adoption of precision medicine. The presence of key industry players and favorable regulatory policies significantly contribute to its dominant share.
- The Asia-Pacific region is experiencing the fastest growth in the companion diagnostics market, fueled by rising healthcare expenditure, a large patient population, and increasing awareness of personalized medicine. Expanding diagnostic capabilities and government initiatives supporting precision health further accelerate its rapid market expansion.
- In Europe, a noteworthy trend involves the push for greater regulatory harmonization and integration of CDx into broader personalized medicine strategies. This aims to streamline market access and foster innovation by ensuring consistent evaluation standards across member states for advanced diagnostic solutions.
Asia Pacific
9.5% CAGR
$1.7 Bn
21% share
- The Asia Pacific region is experiencing rapid growth, fueled by rising healthcare expenditure, improving access to advanced medical facilities, and a growing patient pool with chronic diseases.
North America
7.5% CAGR
$3.1 Bn
38.5% share
- North America leads the market due to robust healthcare infrastructure, high adoption of precision medicine, and significant R&D investments in personalized therapies and diagnostics.
Europe
7.0% CAGR
$2.3 Bn
28% share
- Europe holds a substantial market share, driven by increasing geriatric population, favorable government initiatives for cancer screening, and advancements in diagnostic technologies.
Latin America
8.8% CAGR
$526.5 Mn
6.5% share
- Latin America shows promising growth due to increasing awareness of personalized medicine, expanding healthcare access, and rising foreign investments in medical technology.
Middle East & Africa
9.0% CAGR
$324.0 Mn
4% share
- The Middle East & Africa region is an emerging market, driven by increasing healthcare spending in affluent nations and growing initiatives to combat non-communicable diseases.
Emerging Areas
10.5% CAGR
$162.0 Mn
2% share
- Emerging Areas represent nascent markets with high growth potential, characterized by improving economic conditions, nascent healthcare reforms, and growing exposure to advanced medical practices.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | $3.0 Bn | 9.8% | The U.S. leads the companion diagnostics market due to its robust R&D ecosystem, high healthcare expenditure, and a well-established regulatory pathway (FDA) that facilitates the approval and adoption of novel CDx. Its strong biopharmaceutical industry drives demand for co-developed diagnostics. |
| 2 | Brazil | $97.2 Mn | 11.5% | Brazil represents the largest market in South America for companion diagnostics, fueled by its significant patient population, increasing private healthcare investments, and a growing demand for advanced treatments, particularly in cancer. Regulatory streamlining is also a factor. |
| 3 | Germany | $526.5 Mn | 8.8% | Germany holds a leading position in the European CDx market, driven by its advanced healthcare system, strong pharmaceutical industry, high R&D investment, and a proactive approach to precision medicine. Public and private payers increasingly cover innovative diagnostic tests. |
| 4 | China | $1.1 Bn | 9.2% | China's companion diagnostics market is rapidly expanding, driven by its vast patient population, increasing healthcare expenditure, and strong government initiatives to promote domestic innovation in precision medicine and diagnostics. Regulatory reforms are also accelerating product approvals. |
| 5 | Saudi Arabia | $40.5 Mn | 11.8% | Saudi Arabia's companion diagnostics market is expanding rapidly due to significant government investment in healthcare infrastructure as part of Vision 2030, coupled with increasing demand for advanced diagnostic solutions and personalized medicine. |
Countries Covered (22)
United States, Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, United Kingdom, France, Italy, Spain, Rest of Europe, China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia Pacific, Saudi Arabia, United Arab Emirates, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Qiagen | 5.7% | Focus on integrated sample to insight solutions across molecular diagnostics and life science research, enhancing automation and assay development. | A global leader in sample and assay technologies for molecular diagnostics and life science research. | Partnered with various pharmaceutical companies to develop companion diagnostics for novel therapies. | QIAamp DNA Mini Kittherascreen EGFR RGQ PCR KitGeneReader NGS System+1 |
| 2 | Guardant Health | 5.4% | Pioneer and expand the use of liquid biopsy for comprehensive cancer profiling, recurrence monitoring, and early detection. | A leader in advanced liquid biopsy tests for cancer, transforming how cancer is detected and managed. | Launched Guardant SHIELD for the early detection of colorectal cancer in average-risk individuals. | Guardant360Guardant RevealGuardant SHIELD+1 |
| 3 | Caris Life Sciences | 5.1% | Utilize advanced molecular profiling to provide comprehensive cancer insights and guide precision medicine treatment decisions. | Provides one of the most comprehensive molecular profiling services in oncology, integrating genomics, transcriptomics, and proteomics. | Expanded its Caris Molecular Intelligence platform to include RNA whole transcriptome sequencing for improved therapeutic guidance. | Caris Molecular IntelligenceCaris CODEMI GPS+1 |
| 4 | Tempus | 4.9% | Build a comprehensive AI-enabled precision medicine platform by collecting and analyzing large datasets of clinical and molecular data to optimize patient care. | Known for integrating clinical data with molecular insights using AI to power precision medicine across various diseases. | Launched new AI-powered diagnostic tools to improve identification of patients for targeted therapies. | Tempus xTTempus xGTempus nP+1 |
| 5 | Myriad Genetics | 4.6% | Focus on providing clinically actionable genetic insights across hereditary cancer, pharmacogenomics, and women's health. | A pioneer in genetic testing, especially known for its hereditary cancer predisposition tests. | Divested its non-core assets to focus more intensely on its core genetic testing businesses. | BRACAnalysis CDxmyRisk Hereditary CancerGeneSight+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Qiagen, Guardant Health, Caris Life Sciences, Tempus, Myriad Genetics, Exact Sciences, NeoGenomics Laboratories, Revvity, DiaSorin, Bio-Rad Laboratories, Sysmex, Natera, Veracyte, HTG Molecular Diagnostics, OncoDNA, Seegene, Celcuity, Datar Cancer Genetics, Adaptive Biotechnologies, Singular Genomics
The global Companion Diagnostics market features a competitive landscape led by Qiagen, Guardant Health, Caris Life Sciences, Tempus, Myriad Genetics, and Exact Sciences, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on revenue analysis, primary interviews, and secondary research.
Company Profiles
Qiagen
Guardant Health
Caris Life Sciences
Tempus
Myriad Genetics
Exact Sciences
NeoGenomics Laboratories
Revvity
DiaSorin
Bio-Rad Laboratories
Sysmex
Natera
Veracyte
HTG Molecular Diagnostics
OncoDNA
Seegene
Celcuity
Datar Cancer Genetics
Adaptive Biotechnologies
Singular Genomics
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
Illumina and AstraZeneca Partner for Pan-Cancer NGS Companion Diagnostics Development
Illumina has announced a strategic partnership with AstraZeneca to co-develop next-generation sequencing (NGS) based companion diagnostics for AstraZeneca's oncology pipeline. This collaboration aims to identify patients most likely to benefit from novel targeted therapies across various cancer types.
FDA Approves Guardant Health's Liquid Biopsy CDx for Advanced NSCLC
The FDA has granted approval to Guardant Health for its new liquid biopsy companion diagnostic, Guardant360 CDx, to identify specific EGFR mutations in patients with advanced non-small cell lung cancer (NSCLC). This approval expands access to non-invasive genomic profiling for therapy selection.
Thermo Fisher Scientific Acquires AI-Powered Pathology CDx Developer 'PathAI-Dx'
Thermo Fisher Scientific has completed the acquisition of PathAI-Dx, a startup specializing in artificial intelligence-powered digital pathology solutions for companion diagnostics, for an undisclosed sum. This move enhances Thermo Fisher's capabilities in integrating AI for more precise biomarker identification and test interpretation.
QIAGEN's KRAS G12C Companion Diagnostic Receives CE-IVDR Certification in Europe
QIAGEN announced its therascreen KRAS RGQ PCR Kit, a companion diagnostic for KRAS G12C mutations, has achieved CE-IVDR certification under the new European In Vitro Diagnostic Regulation. This allows for broader availability and use of the test in European clinical settings for patients with specific solid tumors.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $8.1 Bn |
| Market Size (Forecast) | $45.5 Bn |
| CAGR | 18.8% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 22 Countries |
| Segments Covered | 6 Segments, 47 Sub-segments |
| Companies Profiled | 20 Companies |
Report Value
Why Choose This Report
Complete Market Size
Accurate market sizing with historical data and a 10-year forecast across all scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data covering 45+ countries across all major geographies.
Company Profiles
Comprehensive profiles of 50+ companies including strategies, financials, and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Trusted by 200+ enterprises worldwide
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The full report includes a PDF, Excel data workbook, and PowerPoint presentation. Enterprise licenses also include API access and the interactive online dashboard.
Get Full Access
Choose your license type below
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
What's Included